Groundbreaking Casgevy Approval Retrospective

Learn more about the groundbreaking approval of the US' first CRISPR therapy by Vertex Pharmaceuticals and CRISPR Therapeutics, and how it's reshaping the landscape of CRISPR regulations and ongoing clinical trials. Jimi Olaghere, an entrepreneur, sickle cell disease advocate and one of the first patients in the Casgevy clinical trial, shares his perspectives on the impact of this landmark CRISPR therapy on patients' health and future opportunities.

Stay informed and gain valuable insights into the future of CRISPR therapies.